Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
About this item
Full title
Author / Creator
Publisher
Waltham, MA: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
Waltham, MA: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
In this randomized trial involving patients with multiple sclerosis, BG-12 (dimethyl fumarate) reduced clinical relapses, disability progression, and MRI lesions. BG-12 treatment resulted in reduced lymphocyte counts and elevated liver aminotransferase levels.
Oral BG-12 (dimethyl fumarate) is being investigated for the treatment of multiple scl...
Alternative Titles
Full title
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1069209466
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1069209466
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1114287
